The CooperCOO +4.04%85 FCF Yield % is 4.24 as of Jun. 24, 2026, which is 56% above its 10-year median of 2.72. GuruFocus rates COO with a GF Score™ of 85/100 and a GF Value™ of $100.85 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 855 Medical Devices & Instruments companies, The Cooper ranks better than 76.61% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
The Cooper FCF Yield % Related Terms
The Cooper FCF Yield % Historical Data
* Premium members only.
The historical data trend for The Cooper's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, The Cooper's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Cooper FCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, The Cooper's FCF Yield % distribution charts can be found below:
* The bar in red indicates where The Cooper's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Cooper (COO) has a FCF Yield % of 4.24 as of Jun. 24, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on The Cooper and its competitors. This is 56% above median its historical median of 2.72. Over the past decade, The Cooper's FCF Yield % has ranged from 0.63 to 4.90. According to the industry distribution chart, The Cooper ranks #200 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 23.4%.
Is The Cooper's FCF Yield % too high?
The Cooper's current FCF Yield % of 4.24 is 56% above median its 10-year median of 2.72. Over the past 10 years, this metric has ranged from a low of 0.63 to a high of 4.90. Based on the distribution chart, The Cooper ranks #200 out of 855 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, The Cooper has a GF Score™ of 85/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The Cooper's FCF Yield % compare to ALGN and SOLV?
According to the Medical Devices & Instruments industry distribution chart, The Cooper ranks #200 out of 855 companies for FCF Yield %. This places The Cooper in the top 23% of its industry — outperforming the majority of peers. Historically, The Cooper's own FCF Yield % has ranged from 0.63 to 4.90 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Devices & Instruments company?
A good FCF Yield % depends on the Medical Devices & Instruments industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on The Cooper and its competitors. The Cooper's current FCF Yield % is 4.24, which is 56% above median its own 10-year median of 2.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Cooper stock overvalued right now?
Based on GuruFocus' analysis, The Cooper (COO) is currently considered Significantly Undervalued. The stock's GF Value™ is $100.85, compared to a current price of $68.86 — trading 31.7% below its estimated fair value. The current FCF Yield % is 4.24, which is 56% above median its 10-year median of 2.72. The Cooper's overall GF Score™ is 85/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For The Cooper (COO), the current FCF Yield % is 4.24 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Cooper (COO) Overvalued in 2026?
Based on GuruFocus' analysis, The Cooper stock appears to be undervalued.
The current stock price of $68.86 is trading 31.7% below its estimated GF Value™ of $100.85.
GuruFocus considers The Cooper to be Significantly Undervalued.
Key valuation signals for COO:
FCF Yield %: 4.24 (56% above median its 10-year median of 2.72)
GF Value™: $100.85 vs. price of $68.86 (31.7% below fair value)
No single metric tells the full story. See the COO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
85GF Score
Get the complete analysis for COO
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COO has been successfully added to your 
